David G. J. Cucchi

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines

Carolien van Alphen, Jacqueline Cloos, Robin Beekhof et al. · Molecular & Cellular Proteomics · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

David G. J. Cucchi, Barbara Denys, Gertjan J.L. Kaspers et al. · Blood · 2018 · 41 citations · Full text

Life Sciences, Genetics, Molecular Genetics +8

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

David G. J. Cucchi, Carolien van Alphen, Sonja Zweegman et al. · HemaSphere · 2021 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

Tobias B. Polak, David G. J. Cucchi, Joost van Rosmalen et al. · Frontiers in Pharmacology · 2022 · 16 citations · Full text

Health Professions, Pharmacoeconomics, Pharmacology +17

<i>TP53</i> mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia

David G. J. Cucchi, Costa Bachas, Kim Klein et al. · British Journal of Haematology · 2019 · 13 citations · Full text

Life Sciences, Genetics, Hematology +17